IXABEPILONE
![]() |
- ₹0
- Product name: IXABEPILONE
- CAS: 219989-84-1
- MF: C27H42N2O5S
- MW: 506.7
- EINECS:630-424-7
- MDL Number:MFCD04307791
- Synonyms:IXABEPILONE;(1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-1,5,7,9,9-pentamethyl-14-[(E) -1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14. 1.0]heptadecane-8,12-dione;Aza-epothilone B;Bms 247550-1;Ixempra;Ixempra kit;Unii-K27005np0a;Azi-epothilone B
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Melting point :>160°C (dec.)
alpha :D22 -40.7° (c = 1.0 in chloroform)
Boiling point :697.8±55.0 °C(Predicted)
Density :1.122±0.06 g/cm3(Predicted)
storage temp. :Sealed in dry,Room Temperature
solubility :Chloroform (Slightly), Methanol (Slightly)
pka :13.73±0.70(Predicted)
form :White solid.
color :White to Off-White
alpha :D22 -40.7° (c = 1.0 in chloroform)
Boiling point :697.8±55.0 °C(Predicted)
Density :1.122±0.06 g/cm3(Predicted)
storage temp. :Sealed in dry,Room Temperature
solubility :Chloroform (Slightly), Methanol (Slightly)
pka :13.73±0.70(Predicted)
form :White solid.
color :White to Off-White
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Ixabepilone, a semisynthetic analog of epothilone B, was launched for the treatment of metastatic or locally advanced breast cancer. It is indicated for use in combination with capecitabine in patients who have previously failed treatment with an anthracycline such as doxorubicin and a taxane such as paclitaxel. It is also approved as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. Ixabepilone is the first member of the epothilone family of anticancer agents to be approved. Epothilones are novel cytotoxic macrolides derived from bacterial fermentation.Like the taxanes, their mechanism of action involves binding to and stabilizing microtubules, which results in mitotic arrest and apoptosis.
The most common adverse reactions (X20%) associated with ixabelipone as monotherapy or in combination with capecitabine were peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/ mucositis, diarrhea, and musculoskeletal pain. The most common hematologic abnormalities (W 40%) include neutropenia, leukopenia, anemia, and thrombocytopenia. Ixabelipone in combination with capecitabine is contraindicated in patients with AST or ALT W2.5 ULN (upper limit of normal) or bilirubin W1 ULN due to increased risk of toxicity and neutropenia-related death.
More related product prices
Patupilone 188116-07-6 Isoxepac Itraconazole AZD-1208 Ilomastat L-4-THIAZOLYLALANINE 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide PF-04929113 OTAVA-BB 1115529 Tariquidar Esomeprazole magnesium ZLN005 BLU 9931 1 NM-PP1 (-)-Blebbistatin 194423-06-8 Finasteride Doxorubicin hydrochloride CrenolanibRelated product price
- Patupilone
₹4800-22900 - Isoxepac
₹5800-45529.95 - Itraconazole
₹10900-23111.38
Suppliers and manufacturers
A.J Chemicals
CLEARSYNTH LABS LTD.
Pharmaffiliates Analytics and Synthetics P. Ltd
Balaji Medical Services Private Limited
SynZeal Research Pvt Ltd
Pharma Affiliates
Henan Tianfu Chemical Co.,Ltd.